{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:29:01Z","timestamp":1790011741468,"version":"4.0.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Object<\/jats:title>\n                    <jats:p>The occurrence of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) poses a significant challenge in treating non-small-cell lung cancer (NSCLC), limiting the clinical use of EGFR-TKIs. Proteolysis-targeting chimeras (PROTACs) demonstrate promise in preclinical settings. This study is aimed to design effective EGFR degraders by linking CRBN ligands with relatively lower molecular weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Computational methods are employed to do the rational design for the PROTACs. Western blots are used to examine the expression of proteins including EGFR. Cell viability and colony-formation assays are conducted to evaluate the anti-proliferative effects of degraders to NSCLC cell lines, and apoptosis assays are assessed by Annexin V\u2010FITC\/PI dual staining followed by flow cytometry. Female BALB\/c nude mice bearing HCC827 xenografts are administered compound 14 (30 mg\/kg) by intraperitoneal injection and the tumor volume and weights are measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We designed and synthesized a series of highly potent degraders based on the first\u2010generation EGFR\u2010TKI gefitinib and a cereblon (CRBN) ligand. Among these degraders, compound 14, with a relatively low molecular weight of 814.32 Da, exhibits notable activity against EGFR\n                      <jats:sup>Del19<\/jats:sup>\n                      and EGFR\n                      <jats:sup>L858R<\/jats:sup>\n                      , with DC50 values of 0.26 nM and 20.57 nM, respectively, while showing no effect on EGFRwt. Additionally, downstream signaling pathways are significantly inhibited. Mechanistic studies indicate that EGFR degradation depends on the ubiquitin\u2013proteasome system (UPS). Furthermore, compound 14 markedly suppresses the growth of HCC827 cells and induces apoptosis, with a 96\u2010h IC50 value of 4.91 nM, while not affecting the viability of H1299, HeLa, and H1975 cells up to 1 \u03bcM. In the HCC827 cell-derived xenograft model, compound 14 demonstrates substantial anti-tumor activity and effectively reduces EGFR\n                      <jats:sup>Del19<\/jats:sup>\n                      protein levels in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With its low molecular weight and excellent in vitro and in vivo efficacy, compound 14 could serve as a promising lead for developing degrader-based therapies targeting mutated EGFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1604661","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:27:30Z","timestamp":1761283650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted degradation of EGFR 19Del by PROTACs suppresses tumor growth in non-small-cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Lianhua","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangqiu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanzhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Kulpakko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chieng","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.jtho.2016.05.019","article-title":"L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC","volume":"11","author":"Bersanelli","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.jtho.2016.12.024","article-title":"Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC","volume":"12","author":"Chen","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2020.12.039","article-title":"The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance","volume":"153","author":"Fuchs","year":"2021","journal-title":"Lung Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1021\/jacs.2c09387","article-title":"High accuracy prediction of PROTAC complex structures","volume":"145","author":"Ignatov","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1021\/acs.jcim.9b00445","article-title":"CoDockPP: a multistage approach for global and site-specific protein-protein docking","volume":"59","author":"Kong","year":"2019","journal-title":"J. Chem. Inf. Model"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.jtho.2017.02.023","article-title":"Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer","volume":"12","author":"Peled","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1021\/acs.jcim.3c01154","article-title":"Rational prediction of PROTAC-compatible protein-protein interfaces by molecular docking","volume":"63","author":"Pereira","year":"2023","journal-title":"J. Chem. Inf. Model"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.21037\/tcr.2018.09.13","article-title":"EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review","volume":"8","author":"Pisapia","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"113328","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/bioinformatics\/btz062","article-title":"Calculation of accurate interatomic contact surface areas for the quantitative analysis of non-bonded molecular interactions","volume":"35","author":"Ribeiro","year":"2019","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"105605","DOI":"10.1016\/j.bioorg.2022.105605","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy","volume":"120","author":"Shi","year":"2022","journal-title":"Bioorg Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","article-title":"PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes","volume":"60","author":"Zaidman","year":"2020","journal-title":"J. Chem. Inf. Model"},{"key":"B24","doi-asserted-by":"publisher","first-page":"112061","DOI":"10.1016\/j.ejmech.2020.112061","article-title":"Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)","volume":"189","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"112781","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49671","DOI":"10.18632\/oncotarget.17913","article-title":"EGFR G796D mutation mediates resistance to osimertinib","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:27:30Z","timestamp":1761283650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1604661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1604661"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1604661","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"1604661"}}